

Prima BioMed

*Annual General Meeting
CEO Presentation*

November 25, 2015



ASX:PRR; NASDAQ:PBMD



Notice: Forward Looking Statements

The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR; NASDAQ:PBMD). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Prima BioMed and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company's filings to the ASX and SEC for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Prima BioMed's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Prima BioMed's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. This presentation should not be relied on as a recommendation or forecast by Prima BioMed. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

2015 Highlights – a Transformative Year!

○ Planning of 2 new trials – EMA scientific advice

○ Announcement of Final CVac™ OS data

○ Ridgeback \$15M placement

○ SPP \$10M placement

○ Partners beginning trials (GSK and Novartis)

○ New patent filings

○ New Collaborations – NEC/Yamaguchi

Prima Biomed

IMP321 set to progress into Phase IIb study

Prima Biomed is well positioned to push forward with the clinical development of its promising LAG3 programme following an AS25m fund raising and encouraging scientific advice from the EMA for its upcoming Phase III trial of IMP321 in metastatic breast cancer. Novartis and BMS have recently announced clinical trials of advanced LAG3 programmes, providing additional validation for the LAG3 technology that Prima obtained with the 2014 acquisition of Innatecap. We lift our valuation to AS271m (vs AS191m) with the inclusion of the Novartis LAG3 programme now that it has entered the clinic, and a milestone indication for IMP321.

Year end	Revenue	EBIT	EBIT	EPS	EPS	EPS	Total
	(M\$)	(M\$)	(M\$)	(c)	(c)	(c)	(M\$)
2014	22	(12)	(18)	0.00	0.00	0.00	0.00
2015	13	(14)	(24)	0.00	0.00	0.00	0.00
2016	11	(24)	(32)	0.00	0.00	0.00	0.00
2017	12	(14)	(21)	0.00	0.00	0.00	0.00

Novartis moves IMP701 programme into the clinic
 Novartis has initiated a Phase I trial of LAG3, its humanised version of Prima's IMP701 antibody and LAG3 antibody, targeting a novel immune payment. Novartis will trial LAG3 in cancer patients both as a single agent and in combination with its immune checkpoint inhibitor PD-018, underscoring the potential benefits that it sees from targeting LAG3.

IMP321 Phase IIIb trial in breast cancer to start Q416
 Prima is poised to initiate a Phase III trial of lead product IMP321 (a soluble LAG3 fusion protein) in combination with chemotherapy in metastatic breast cancer in Q416. The European regulator (EMA) has suggested that the trial could be sufficient to support a marketing authorisation in advanced breast cancer patients. The trial is expected to take three years, so results are likely in H218. Prima also plans to launch a Phase I study of IMP321 in combination with an anti-PD1 immune checkpoint inhibitor in melanoma patients in early 2016.

Ridgeback funding approved – funded to late 2018
 Prima has raised AS25m since May, including AS15m from Ridgeback Capital (including AS13.75m in convertible notes, approved by shareholders in July) and an AS10m SPV. Prima now has the resources to initiate the pivotal Phase III trial of IMP321 in metastatic breast cancer and a Phase I combination trial. The company indicated that it has sufficient cash to fund operations until late 2018.


Valuation: Increased to AS271m, 13c per share
 We have increased our valuation to AS271m (vs AS191m), with the biggest contributors to the increase being the inclusion of the Novartis LAG3 programme now that it has entered the clinic, and a milestone indication for IMP321. Our valuation is equal to 13c per share on an included basis (vs 14c), or 10c per share after accounting for dilution from options, warrants and convertible notes (vs 10c).

Clinical update

Pharma & biotech

19 October 2015

Price AS26.06
 Market cap AS117m
 US\$174m
 Call (2014-18) September 2015 263c
 Share price 2015c 263c
 Div Yield 0%
 Cash 1000000
 Price change 100%
 Dividend coverage 1000000
 Share price performance



Business description
 Prima Biomed is an oncology biotechnology company focused on cancer immunotherapy. Its pipeline includes three products targeting LAG3 (immune activation), IMP701 (a soluble LAG3 fusion protein) and potential products IMP321 (SPV) and IMP321 (antibody). It also has a Phase I trial in melanoma patients.

Next events
 Start IMP321 Phase III in breast cancer Q416
 Start IMP321 combination Phase I in melanoma

Analysis
 Share price 45.00 AS26.06
 Dividend yield 0.00%
 Dividend cover 1000000
 Cash 1000000
www.primabiomed.com
 @primabiomed

Prima Biomed is a research client of Edison Investment Research Limited

H.C. WAINWRIGHT & CO. Initiating Coverage
 Healthcare
 October 14, 2015

Prima Biomed Ltd. (PBMD) Research Analyst, Ph.D. 210 388 0100
Rating: Buy analyst@hainwright.com

Deep Dive
210 388 0100
www.hainwright.com

Leading the LAG-3 Race; Initiating with a Buy and \$3.00 PT

Stock Data	10/14/2015
Price	\$2.22
Exchange	NASDAQ
Price Target	\$3.00
52-Week High	\$6.48
52-Week Low	\$0.43
Enterprise Value (MM)	\$76
Market Cap (MM)	\$61
Public Market Float (MM)	\$2.1
Shares Outstanding (MM)	66.2
3 Month Avg Volume	1,433,870
Short Interest (MM)	0.91

Key All over information are reported in our report at:

Balance Sheet Metrics	AS14	AS15	AS16	AS17
LAG3 (MM)	AS13.75			
Total Debt (MM)	AS1.51			
Total Cash/Equity	AS1.21			
Book Value/Share	AS0.41			

Key Ratios	2015A	2015E	2017E
1st Half	0.00	0.00	0.00
2nd Half	(0.02)	0.00	0.00
FY	(0.02)	(0.00)	(0.01)

Revenue (MM)	2015A	2015E	2017E
1st Half	2.1	1.3	1.5
2nd Half	0.1	0.0	0.0
FY	2.1	1.3	1.5

Unique and broadly applicable therapies. The competitor products under development are mostly antibody antibodies against LAG3 (similar to IMP-701), and we believe Prima is the only company developing therapies that use LAG3 as an immune adjuvant (IMP-321) or target LAG3 for autoimmune diseases (IMP-721). In our view, a key benefit of immunotherapy is that the immune system is highly adaptive. By exploiting the different immunological functions of LAG3, we believe that these therapies could potentially be used to treat a broad range of cancers and autoimmune diseases. To remain competitive in our estimates, we are only accounting for revenues from the initial indications of mBC and metastatic melanoma (IMP-321), melanoma and lung cancer (IMP-701), and severe psoriasis (IMP-721) in our financial projections. Any new indications beyond these would be an update to our projections.

Valuation. We derived our 12-month price target of \$3.00 per diluted ADS based on the average of two valuation methods: 1) price-sales multiple analysis applying an 8x multiple to our 2022 (re-adjusted) revenue estimate of AS768m discounted at 12%, and 2) price-earnings multiple analysis applying an 18x multiple to our 2022 (re-adjusted) earnings of AS16.02 discounted at 12%. Please refer to the valuation section on page 6 for details.

For definitions and the distribution of analyst ratings, analyst contributions, and other disclosures, please refer to pages 20 - 21 of this report.

We have raised Prima's market profile


Improved market standing

Institutional and independent sell-side interest

Active marketing of the new Prima story




Our stock is now actively traded in the US



Prima attracting institutional grade

- Market cap – now >US\$70m
- Specialist healthcare funds now on register
- ~30% of stock now held in ADRs



Prima SP YTD benchmark



Participation at Investor and Industry Events

Investor Meetings

- Multiple Roadshows
- JP Morgan Jan 2015
- Bioshares July 2015
- Rodman & Renshaw Sep 2015
- Leerink Sept 2015

Business Development

- AusBiotech Oct 2015
- BioEurope Nov 2015
- Multiple other contacts

Scientific Conferences

- ASCO May 2015
- SITC Nov 2015
- Checkpoint Conf Nov 2015

Technology




Immune Checkpoints

- Checkpoints are hot – Prof Frédéric Triebel interviewed about LAG-3 in Nature Biotechnology interview – published July 2015 (Volume 15pp673-675)
- Immune checkpoints are junctions in immune signalling mechanisms between cells where decisions are made – make good targets for therapies

IMP321

Soluble dimeric recombinant form of LAG-3 (fusion protein)



- Highly efficacious in multiple animal models of cancer and infectious disease
- Shown to be safe, non-immunogenic and efficacious in humans
- At low doses can be used as a T cell adjuvant for cancer vaccines

(Clin Cancer Res. 2008 Jun 1;14(11):3545-54)

Chemo-Immunotherapy: IMP321

Treatment of cancer cells with chemotherapy, radiotherapy or other drugs will kill off the cells causing tumour debris to be created and antigen release.

Adding an APC activator like IMP321 post cancer treatment enhances antigen uptake by APC's. They then migrate to lymph nodes and present a wide range of cancer antigens to CD8 T cells which then actively seek and destroy tumours.

Other Applications: IMP321

IMP321 can be combined with other immune checkpoint treatments to help drive optimal immune responses to cancer (eg upcoming combo study)

IMP321 can be used as an adjuvant in vaccine combination studies where it helps to boost the magnitude of an antigen specific response (e.g. NEC/Yamaguchi collaboration)

Upcoming trials

- AIPAC
- Ph I Combo pilot



Planned Phase IIb Chemoimmunotherapy in MBC: AIPAC trial

- Multicentre, randomised, double blind, placebo-controlled
- 15 + 196 patients: IMP321 + paclitaxel vs. paclitaxel + placebo
- Primary objective: efficacy (as Progression-Free Survival)
- Scientific advice from EMA received in July 2015
- Trial initiation expected in Q4 2015
- Belgium regulatory approval received in October 2015

Planned Phase I Study in Immuno-Oncology Combination

- Multicentre, open label, dose escalation
- Up to 30 patients with unresectable or metastatic melanoma
- IMP321 + Anti-PD-1 combination study
- Primary objective: safety, tolerability
- Trial initiation expected in Q1 2016

Major Addressable Markets in MBC



Metastatic Breast Cancer

- Annual global incidence of 1.67M new cases of all breast cancer
- Standard of care is variable but includes hormone therapy, chemotherapy and targeted therapies.
- We are specifically targeting Her2- cancer; refractory to hormone therapy.
- Five year survival rate is 22% (American Cancer Society)
- Sales of all breast cancer drugs are estimated to grow from \$9.8Bn to \$18.2Bn/year by 2023
([Pharmatimes](#), 2015)

Partnership Updates



IMP731

for Autoimmune Diseases



GSK's investigational product, GSK2831781, which is derived from IMP731 antibody, aims to kill the few activated LAG-3+ T cells that are auto-reactive in autoimmune disease leading to long term disease control without generalised immune suppression

- GlaxoSmithKline holds exclusive WW rights to IMP731
- Jan 2015: Prima announced a single-digit million US\$ milestone
- Up to £64m in total upfront and milestones + royalties
- GSK2831781 in Phase I trials with potential regulatory filing expected within 2021-2025 timeframe (See from slide 108 of [GSK investor presentation](#))
- Phase II expected to initiate in 2016


IMP701: Antagonist mAb

IMP701 is an anti-LAG-3 antibody that blocks LAG-3-mediated immune down-regulation

LAG-3 is a prime target for immune checkpoint blockade as it is readily expressed at a high level in many human tumours.

- Novartis holds exclusive WW rights
- Aug 2015: Start of Phase 1 study **by Novartis** (Novartis milestone payment to be received for IMP701 Phase 1 initiation)
- LAG-525 to be used in combination with PD-1 in solid tumours before end of this year
(See slide 10 of [Novartis IR presentation](#))

Other Partnerships



Upcoming Milestones


Clinical

- Q4 2015: Initiation of AIPAC (metastatic breast cancer) // First data in 2016 (e.g. safety/PK)
- Q1 2016: Initiation of Anti-PD-1 combination Phase I study (melanoma) // First data in 2016 (e.g. safety/PK)
- Expected commencement of Phase II study with IMP731 (GSK)
- Continued development of Phase I study IMP701 (Novartis)

Other

- Ongoing discussions re CVac
- Strategic partnering and collaboration discussions re IMP321
- Progress in IP
- Ongoing investor relations efforts

A solid foundation





PRIMA BIOMED

NASDAQ: PBMD, ASX: PRR

Thank you!